Events

New tech brings new hope in our new normal w/ Joanna Shields, WeAreTechWomen

26 JUNE 2020 | VIRTUAL EVENT

Abstract

In recent months the coronavirus pandemic has thrust our global society into a ‘new normal’ which has served as a powerful reminder of the fragile nature of life and health. However, we possess a powerful ally to fight back — AI. In this talk, Joanna Shields will demonstrate how human intelligence partnered with technology promises to accelerate new discoveries, new treatments, and new hope for patients.

Joanna Shields

Joanna Shields (Baroness Shields OBE) is a tech industry veteran with a successful track record building some of the world’s best-known companies. Her career spans over 30 years and has focussed on harnessing the power of technology to drive change that improves connectivity, humanity and society. Prior to joining BenevolentAI, Joanna served as the UK’s first Minister for Internet Safety and Security, Under Secretary of State, Special Advisor on the Digital Economy, and Chair & CEO of TechCityUK.  Before her government service, Joanna held executive roles at Google, Facebook, Bebo/Aol, Decru, RealNetworks, Veon and EFI and served as a non-executive director of the London Stock Exchange Group and TalkTalk Telecom Group.

Joanna founded WePROTECT.org, a multi-stakeholder global alliance working to protect children from online abuse and exploitation. She is a member of the Council on Foreign Relations, the Transatlantic Commission on Election Integrity and the Child Dignity Alliance. In 2014, Joanna was appointed OBE for services to digital industries and voluntary service to young people and made a Life Peer of the House of Lords.

REGISTER >

More Posts

You Might Also Like

Blog
Tech Nation Visa: the gateway to world-leading UK tech jobs
Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.
Feb 19, 2021
News
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Feb 11, 2021
News
BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target
BenevolentAI and AstraZeneca hit collaboration milestone with an AI-generated CKD target from the partnership entering AstraZeneca’s portfolio.
Jan 27, 2021
News
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.
Jan 15, 2021
Blog
Joanna Shields speaks at the Global Partnership on Artificial Intelligence
BenevolentAI CEO Joanna Shields opened the final plenary of the Global Partnership on Artificial Intelligence (GPAI) summit with a powerful message on the future of AI.
Dec 11, 2020
Blog
BenevolentAI wins Innovation Award at 2020 Scrip Awards
BenevolentAI wins the Innovation Award at the prestigious 2020 Scrip Awards for our work in artificial intelligence applied drug discovery.
Dec 11, 2020